CEO Yoon Ki-Young had been responsible for the development, production and registration of botulinum toxin injection medicine for more than 10 years since the establishment of the first botulinum toxin injection company in Korea. 

​

   When he was involving in the development of new botuliun toxin injection medicine in ATGC Co., Ltd., who has secured botulinum toxin strain and has been developing botulinum toxin medicine. He planed to develop botulinum toxin-derived recombinant protein materials that can penetrate skin and target cell by the combination of 'Botulinum Toxin Light Chain A' with skin and cell permeation technologh of Procell Therapeutics Co., Ltd., And then he had coordinated and supported this research. 

     

   Two years later, this ingredient was finally developed. He recalls that he couldn't believe the feedback of showing efficacy at th first sample stage, and he never thought it would succeed in such a short time. The idea of a botulinum-derivative raw material in the form of applying on the skin was not the idea nobody could think. Topical Botulinum Toxin is a technology that has already been dreamed in the botulinum toxin industry worldwide for over 15 years. It is a result based on his experience of reviewing and verifying the technology with a various of company that has skin penetration technologies around the world. 

 

   As a result, he has developed a career of developing from botulinum toxin medicine injection to topical botulinum toxin. Currently, he is trying to develop safe and effective cosmetics with experience and perspective in medicine field dealing with biochemical products.

   And he starts a new challenge to develop medicines using these innovative ingredients.